Track topics on Twitter Track topics that are important to you
BASEL (dpa-AFX) - Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvove...
Original Article: Spark Therapeutics' One-time Gene Therapy LUXTURNA Gets EU ApprovalNEXT ARTICLE
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...